Synonyms: compound 16e [PMID: 36516047] | SZUH-280
Compound class:
Synthetic organic
Comment: SZUH280 is a PROTAC type degrader of the epigenetic regulator histone deacetylase 8 (HDAC8) protein [5]. Structurally it is a chimeric molecule containing the HDAC8 inhibitor PCI-34051 [1], linked to the cereblon (CRBN)-binding ligand pomalidomide to direct the HDAC8 protein for ubiquitination and proteasomal degradation. HDAC8 is an oncology drug target whose expression is upregulated in a range of aggressive cancers. Selective inhibtion of HDAC8 [4], or downregulation through protein degradation [2-3,6] is being widely investigated for anti-tumour potential. SZUH280 is an HDAC8 degrading tool that promotes solid tumour regression in vivo.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. (2008)
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 22 (5): 1026-34. [PMID:18256683] |
2. Chotitumnavee J, Yamashita Y, Takahashi Y, Takada Y, Iida T, Oba M, Itoh Y, Suzuki T. (2022)
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb), 58 (29): 4635-4638. [PMID:35311871] |
3. Darwish S, Ghazy E, Heimburg T, Herp D, Zeyen P, Salem-Altintas R, Ridinger J, Robaa D, Schmidtkunz K, Erdmann F et al.. (2022)
Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity. Int J Mol Sci, 23 (14). DOI: 10.3390/ijms23147535 [PMID:35886887] |
4. Fontana A, Cursaro I, Carullo G, Gemma S, Butini S, Campiani G. (2022)
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors. Int J Mol Sci, 23 (17). DOI: 10.3390/ijms231710014 [PMID:36077415] |
5. Huang J, Zhang J, Xu W, Wu Q, Zeng R, Liu Z, Tao W, Chen Q, Wang Y, Zhu WG. (2023)
Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity. J Med Chem, 66 (2): 1186-1209. [PMID:36516047] |
6. Sun Z, Deng B, Yang Z, Mai R, Huang J, Ma Z, Chen T, Chen J. (2022)
Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8. Eur J Med Chem, 239: 114544. [PMID:35759908] |